Abstract
Solid organ transplant recipients are at a significantly increased risk of developing skin cancer. Both systemic and topical retinoids are useful for chemosuppression of skin cancer in this patient population. These drugs can reduce both the present extent and the future development of premalignant and malignant skin lesions. This paper reviews the current data on the chemoprophylactic properties of topical and systemic retinoids. A practical guide for their use in organ transplant recipients is provided. Specific recommendations for implementing and maintaining therapy, as well as appropriate management and monitoring of adverse events, are presented.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
